Chen Huixia, Gong Siqiao, Zhang Hongyong, Chen Yongming, Liu Yonghan, Hao Junfeng, Liu Huafeng, Li Xiaoyu
Institute of Nephrology, and Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-Communicable Diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, China.
Zhanjiang Institute of Clinical Medicine, Central People's Hospital of Zhanjiang, Guangdong Medical University Zhan-jiang Central Hospital, Zhanjiang, 524001, China.
Cell Death Discov. 2024 Feb 16;10(1):84. doi: 10.1038/s41420-024-01850-6.
Transcription factor EB (TFEB), known as a major transcriptional regulator of the autophagy-lysosomal pathway, regulates target gene expression by binding to coordinated lysosomal expression and regulation (CLEAR) elements. TFEB are regulated by multiple links, such as transcriptional regulation, post-transcriptional regulation, translational-level regulation, post-translational modification (PTM), and nuclear competitive regulation. Targeted regulation of TFEB has been victoriously used as a treatment strategy in several disease models such as ischemic injury, lysosomal storage disorders (LSDs), cancer, metabolic disorders, neurodegenerative diseases, and inflammation. In this review, we aimed to elucidate the regulatory mechanism of TFEB and its applications in several disease models by targeting the regulation of TFEB as a treatment strategy.
转录因子EB(TFEB)是自噬-溶酶体途径的主要转录调节因子,通过与协调的溶酶体表达和调控(CLEAR)元件结合来调节靶基因表达。TFEB受到多种调控,如转录调控、转录后调控、翻译水平调控、翻译后修饰(PTM)和核竞争调控。在缺血性损伤、溶酶体贮积症(LSDs)、癌症、代谢紊乱、神经退行性疾病和炎症等多种疾病模型中,对TFEB进行靶向调控已成功用作一种治疗策略。在本综述中,我们旨在通过将TFEB的调控作为一种治疗策略,阐明TFEB的调控机制及其在多种疾病模型中的应用。